Vimarsana
Biggest News Aggregation in the World

Page 7 - Dana Walker News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dana Walker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dana Walker Today - Breaking & Trending Today

Exclusive: Miss Universe R'Bonney Gabriel on visiting South Africa - Vimarsana News

Exclusive: Miss Universe R'Bonney Gabriel on visiting South Africa

Miss Universe R'Bonney Gabriel spoke to The South African on what her time in South African has been like while on the Miss SA red carpet.

Bogalusa schools four-day school week - Vimarsana News

Bogalusa schools four-day school week

Bogalusa will now be one of the few districts in the state to switch to a four-day school week.

Source: wdsu.com
Nivolumab, Chemotherapy Combination Significantly Improve Overall Survival in Patients With Bladder Cancer - Vimarsana News

Nivolumab, Chemotherapy Combination Significantly Improve Overall Survival in Patients With Bladder Cancer

Nivolumab-based combinations have shown significant survival benefits across several tumor types, including melanoma and advanced renal cell carcinoma.

Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial - Vimarsana News

Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial

CheckMate -901 is the first and only Phase 3 trial with an immunotherapy-based combination to demonstrate a survival benefit compared to standard-of-care cisplatin-based combinations in the first-line treatment of this patient population

First-line Nivolumab Plus Chemo Provides Survival Benefit in Metastatic Urothelial Carcinoma - Vimarsana News

First-line Nivolumab Plus Chemo Provides Survival Benefit in Metastatic Urothelial Carcinoma

Frontline treatment with the combination of nivolumab and cisplatin-based chemotherapy, followed by nivolumab monotherapy, led to a statistically significant improvement in PFS and OS vs standard cisplatin-based chemotherapy regimens alone in previously untreated, cisplatin-eligible patients with unresectable or metastatic urothelial carcinoma.